Moreover, authors found a correlation between high expression of HER2-ECD and cytotoxic T cell response: this observation could explain the better prognosis of trastuzumab-treated patients showing high tumor-infiltrating lymphocytes (130). This evidence concerns the gene ERBB2 and neoplasm.